力生制药：2025年前三季度净利润约3.71亿元

Core Viewpoint - Lisheng Pharmaceutical reported a slight decline in revenue for the first three quarters of 2025, but a significant increase in net profit and earnings per share, indicating strong profitability despite revenue challenges [1] Financial Performance - Revenue for the first three quarters of 2025 was approximately 1.007 billion yuan, a year-on-year decrease of 1.61% [1] - Net profit attributable to shareholders was about 371 million yuan, reflecting a year-on-year increase of 119.05% [1] - Basic earnings per share reached 1.44 yuan, up 118.18% year-on-year [1] Market Position - As of the report date, Lisheng Pharmaceutical's market capitalization stood at 6.1 billion yuan [1]